Biomarkers Archives | Oncotarget

Oncotarget News

Comprehensive Genomic Testing Reveals Treatment Targets in 90% of Advanced Solid Tumors

July 29, 2025

The broad capabilities of the OncoExTra assay detected therapeutically actionable and other clinically relevant genomic events that can inform clinical decision-making for patients with advanced solid tumors.”BUFFALO, NY - July... read more

Oncotarget

microRNAs Emerge as Biomarkers and Diagnostic Tools in Soft Tissue Sarcoma

July 18, 2025

miRNAs are pivotal in regulating gene expression in STS and have been recognized as crucial biomarkers for the diagnosis, prognosis, and therapeutic decision-making in patients.”BUFFALO, NY - July 18, 2025 –... read more

Oncotarget

Precision Medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 Expression

November 6, 2024

This study presents an observational, cross-sectional analysis of 64 patients diagnosed with small cell lung cancer (SCLC) at a reference laboratory for thoracic pathology between 2022 and 2024.”BUFFALO, NY -... read more

Oncotarget

BTK Inhibitor-related Cardiotoxicity: The Quest for Predictive Biomarkers and Improved Risk Stratification

June 4, 2024

due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.”BUFFALO, NY- June 4, 2024 –... read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”BUFFALO, NY- June... read more

Oncotarget

Behind the Study: Role of Biomarkers in Management of Lumps in the Breast

May 10, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a recent research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the... read more

Figure 2: Comparison of human LY6 gene expression in normal uterine tissue (n = 146) to expression in uterine corpus endometrial carcinoma (n = 547).

Oncotarget

LY6 Gene Family: Potential Tumor Antigens and Prognostic Biomarkers in Endometrial Cancer

May 8, 2023

Importantly, the expression of several LY6 genes is elevated in UCEC [uterine corpus endometrial carcinoma] when compared to the expression in normal uterine tissue.”BUFFALO, NY- May 8, 2023 – A... read more

Oncotarget

Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast

May 2, 2023

A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system.”BUFFALO, NY- May 2, 2023 –... read more

Oncotarget

Oncotarget | HALP Score: Prognostic Ability in Cancers – A Literature Review

March 6, 2023

In the last several years, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has emerged in the literature as a new prognostic biomarker [...]” BUFFALO, NY- March 6, 2023 – A new... read more

Oncotarget

Oncotarget | Expression of p-STAT3 and c-Myc Correlates With P2-HNF4α Expression in Nonalcoholic Fatty Liver Disease (NAFLD)

December 6, 2022

In conclusion, our results suggest that STAT3 phosphorylation occurs in livers with NAFLD only in the subset with P2-HNF4α expression, and c-Myc expression is strongly correlated with STAT3 phosphorylation.”BUFFALO,... read more